MedTrace Logo

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2013-01-04

No results posted yet for this study

Summary

This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

NXY-059

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca NXY-059 Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00075959 on ClinicalTrials.gov